Residency · Residency · Medicine Pediatrics
Celiac Disease: Diagnosis and Management Across Ages
Overview
Celiac disease is an autoimmune enteropathy triggered by gluten in genetically predisposed individuals (HLA-DQ2/DQ8). It affects approximately 1% of the population worldwide. Pediatric presentations classically include failure to thrive and diarrhea, while adults more often present with anemia, osteoporosis, or subtle symptoms. Serologic testing, biopsy indications, and long-term monitoring approaches differ between pediatric and adult practice guidelines.
Pathophysiology
Gluten (gliadin peptides from wheat, barley, rye) crosses the intestinal epithelium. Tissue transglutaminase (tTG) deamidates gliadin, creating neoepitopes with high affinity for HLA-DQ2 (90% of patients) or HLA-DQ8 (5-10%) Adaptive immune response: CD4+ T cells drive inflammation, crypt hyperplasia, and villous atrophy in the proximal small bowel. Autoantibodies: anti-tTG IgA, anti-endomysial antibodies (EMA), anti-deamidated gliadin peptides (DGP) The disease process requires: genetic susceptibility (HLA-DQ2/8) + environmental trigger (gluten) + immune activation.
Epidemiology
Prevalence: approximately 1% globally; most are undiagnosed (celiac iceberg) Female-to-male ratio: 2-3:1. First-degree relatives: 5-10% prevalence. Associated conditions with increased risk: type 1 diabetes (5-10%), Down syndrome (5-12%), Turner syndrome (4-8%), autoimmune thyroiditis (2-5%), Williams syndrome, IgA deficiency, other autoimmune diseases. Age of presentation: can occur at any age after gluten introduction; bimodal peaks in childhood (1-5 years) and adulthood (30-50 years)
Clinical Presentation
Pediatric (Classic)
Infants/toddlers (6 months - 3 years): diarrhea, abdominal distension, failure to thrive, anorexia, irritability, muscle wasting; onset typically 1-6 months after gluten introduction. Older children: abdominal pain, diarrhea or constipation, short stature (may be the only finding), delayed puberty, dental enamel defects (permanent teeth), iron deficiency anemia refractory to oral supplementation. Atypical/silent presentations: increasingly recognized; monosymptomatic (isolated anemia, short stature, elevated transaminases, recurrent aphthous stomatitis, arthritis)
Adult
Classic GI: chronic diarrhea, bloating, weight loss, steatorrhea (minority of adult presentations) Atypical/extraintestinal (majority of adult presentations): iron deficiency anemia (most common adult presentation), osteoporosis/osteopenia, fatigue, peripheral neuropathy, ataxia, elevated liver enzymes, infertility/recurrent pregnancy loss, dermatitis herpetiformis. Silent celiac disease: positive serology and villous atrophy but asymptomatic; detected through screening of high-risk groups. Potential (latent) celiac disease: positive serology but normal biopsy; may progress to villous atrophy over time.
Diagnosis
Serologic Testing
| Test | Sensitivity | Specificity | Key Notes |
|---|---|---|---|
| tTG-IgA | >95% | >95% | First-line; must check total IgA simultaneously |
| EMA (IgA) | 90-95% | ~100% | Confirmatory; highly specific |
| DGP-IgA/IgG | 80-95% | 90-95% | Useful in children <2 years and IgA deficiency |
| tTG-IgG | 70-90% | 95% | Use if IgA deficient |
| Total serum IgA | — | — | Rule out IgA deficiency (2-3% of celiac patients) |
First-line: tTG-IgA (tissue transglutaminase IgA) -- sensitivity and specificity >95%. Total serum IgA: MUST check simultaneously (IgA deficiency occurs in 2-3% of celiac patients, causing false-negative tTG-IgA) If IgA deficient: use tTG-IgG and/or DGP-IgG (deamidated gliadin peptide IgG) EMA (endomysial antibody): highly specific (nearly 100%) but less sensitive; useful as confirmatory test. DGP (deamidated gliadin peptide): IgA and IgG; particularly useful in children <2 years where tTG-IgA may be less reliable. Important: patient must be consuming gluten at time of testing (minimum 2-4 weeks of gluten-containing diet; ideally 6-8 weeks for most reliable results)
Duodenal Biopsy (Gold Standard for Adults)
Upper endoscopy with at least 4 biopsies from distal duodenum and 2 from duodenal bulb. Marsh classification: Marsh 0: normal. Marsh 1: increased intraepithelial lymphocytes (>25 per 100 enterocytes) Marsh 2: crypt hyperplasia + increased IELs. Marsh 3: villous atrophy (3a partial, 3b subtotal, 3c total) + crypt hyperplasia + increased IELs. Marsh 3 is diagnostic of celiac disease in the appropriate serologic/clinical context. Patchy distribution: multiple biopsies essential to avoid sampling error.
No-Biopsy Diagnosis (ESPGHAN Pediatric Approach)
ESPGHAN 2020 guidelines allow diagnosis WITHOUT biopsy if ALL criteria are met: Symptomatic child. tTG-IgA >=10x upper limit of normal (on two separate blood draws) Positive EMA on a second blood sample. HLA-DQ2/DQ8 is supportive but NOT required per updated guidelines. Rationale: very high tTG-IgA levels have >95% positive predictive value for Marsh 3 histology. NOT universally adopted in North America -- some North American gastroenterologists still require biopsy confirmation in all cases.
Adult Diagnosis
ACG/AGA guidelines: biopsy is recommended for ALL adults with positive serology. No-biopsy approach for adults is being studied but not yet guideline-endorsed. Exception: dermatitis herpetiformis with positive serology confirms celiac disease without intestinal biopsy.
HLA Typing
HLA-DQ2 or HLA-DQ8 present in >99% of celiac patients. Negative HLA-DQ2/DQ8 essentially excludes celiac disease (very high negative predictive value) Useful for: excluding celiac in patients already on GFD, screening first-degree relatives, resolving equivocal cases.
Management
Gluten-Free Diet (GFD) -- Cornerstone of Treatment
Lifelong strict avoidance of wheat, barley, and rye. Oats: pure, uncontaminated oats are tolerated by most celiac patients; may cross-react in a small subset (~5%) Threshold: <20 ppm gluten per FDA labeling standards. Dietitian referral: essential at diagnosis; education on hidden gluten sources (sauces, dressings, medications, communion wafers, cross-contamination) Compliance assessment: dietary review, repeat serology (tTG-IgA should normalize within 6-12 months on GFD) Mucosal healing: may take 1-2 years in children, 2-5 years in adults; children heal faster than adults on average.
Nutritional Assessment and Supplementation
Iron, folate, vitamin B12: check and supplement if deficient. Vitamin D and calcium: check 25-OH vitamin D; supplement to prevent/treat osteopenia. Zinc, copper, fat-soluble vitamins (A, D, E, K): assess in severe malabsorption. Bone density (DXA): check in adults at diagnosis and follow if abnormal; pediatric DXA if growth concerns or prolonged untreated disease.
Monitoring
Repeat tTG-IgA at 6 and 12 months after starting GFD, then annually. Clinical symptom assessment. Growth monitoring in children (height, weight, growth velocity, pubertal staging) CBC, ferritin, vitamin D, liver enzymes, thyroid function periodically. Repeat biopsy: consider if persistent symptoms or persistently elevated serology despite reported GFD compliance; routine follow-up biopsy is debated. Screening for associated autoimmune conditions: thyroid disease, type 1 diabetes.
Refractory Celiac Disease
Persistent symptoms and villous atrophy despite strict GFD for >=12 months. Rule out: inadvertent gluten exposure (most common cause), alternative diagnoses (microscopic colitis, SIBO, lactose intolerance, IBS) Type I refractory: normal IEL phenotype; responds to immunosuppression (budesonide, azathioprine) Type II refractory: aberrant IEL phenotype (clonal T-cell population); risk of enteropathy-associated T-cell lymphoma (EATL); poor prognosis; hematology referral.
Emerging Therapies
Gluten-degrading enzymes (e.g., latiglutenase): adjunctive to GFD; clinical trials ongoing. Tight junction modulators (larazotide acetate): prevents gluten-induced intestinal permeability; trial results mixed. Immune tolerance approaches: nanoparticle-encapsulated gliadin, peptide immunotherapy. None are yet approved to replace the GFD.
Complications of Untreated Celiac Disease
Malabsorption with micronutrient deficiencies; Osteoporosis and fractures; Infertility and adverse pregnancy outcomes; Increased risk of lymphoma (enteropathy-associated T-cell lymphoma, non-Hodgkin lymphoma) Increased risk of small bowel adenocarcinoma; Hyposplenism (increased encapsulated organism infection risk); Neurological: peripheral neuropathy, gluten ataxia; Dental enamel defects (if untreated during permanent tooth formation).
<image>A diagnostic algorithm for celiac disease showing pediatric and adult pathways. Starting with clinical suspicion, both pathways proceed to tTG-IgA plus total serum IgA. The pediatric branch shows the ESPGHAN no-biopsy pathway (tTG-IgA greater than or equal to 10x ULN on two samples plus positive EMA) alongside the traditional biopsy pathway. The adult branch shows mandatory biopsy per ACG guidelines. Each terminal node shows the diagnosis (confirmed celiac, potential celiac, celiac excluded) with the corresponding management action. HLA-DQ2/DQ8 testing is shown as a useful adjunct for excluding celiac disease in equivocal cases.</image>
<image>An illustration of the Marsh classification of celiac histology showing four panels of duodenal mucosa cross-sections: Marsh 0 (normal villi, normal IELs), Marsh 1 (normal villi, increased IELs highlighted in orange), Marsh 2 (crypt hyperplasia with increased IELs and elongated crypts), and Marsh 3 (villous atrophy with flat mucosa, crypt hyperplasia, and dense IEL infiltration). Each panel is labeled with the histologic features and the clinical significance. An arrow below shows that only Marsh 3 is diagnostic of celiac disease in the appropriate clinical context.</image>
<image>A clinical presentation comparison between pediatric and adult celiac disease. The pediatric column shows a child with abdominal distension, failure to thrive on a declining growth chart, dental enamel defects, and a stool sample representing diarrhea. The adult column shows an adult with laboratory abnormalities (iron deficiency anemia, low vitamin D, elevated transaminases), a DXA scan showing osteoporosis, dermatitis herpetiformis lesions on elbows, and a depiction of peripheral neuropathy. A central column shows overlapping features: fatigue, abdominal pain, bloating, and weight loss.</image>
Clinical Pearls
Always check total serum IgA with tTG-IgA -- IgA deficiency (2-3% of celiac patients) causes false-negative results. In children <2 years, tTG-IgA may be less reliable -- consider adding DGP-IgA/IgG. The ESPGHAN no-biopsy pathway (tTG-IgA >=10x ULN plus positive EMA on second sample) is validated in children and increasingly adopted in Europe but not universally accepted in North America. Patients must be on a gluten-containing diet at the time of serologic testing -- premature GFD causes false-negative results. Celiac disease can present with isolated short stature, iron deficiency anemia, or elevated transaminases without GI symptoms -- screen broadly. A negative HLA-DQ2/DQ8 essentially excludes celiac disease (>99% NPV) -- this is the most useful test for ruling OUT celiac. Type II refractory celiac disease carries a risk of lymphoma and requires hematology referral. Growth and puberty typically catch up completely with a strict GFD if celiac disease is diagnosed and treated before epiphyseal closure. Dermatitis herpetiformis (intensely pruritic vesicles on elbows, knees, buttocks) is pathognomonic for celiac disease -- skin biopsy with granular IgA deposits confirms the diagnosis.
References
- Husby S, Koletzko S, Korponay-Szabo IR, et al. European Society for Paediatric Gastroenterology, Hepatology, and Nutrition guidelines for diagnosing coeliac disease 2020. J Pediatr Gastroenterol Nutr. 2020;70(1):141-156.
- Rubio-Tapia A, Hill ID, Semrad C, et al. American College of Gastroenterology clinical guideline: diagnosis and management of celiac disease. Am J Gastroenterol. 2023;118(1):59-76.
- Green PHR, Lebwohl B, Greywoode R. Celiac disease. J Allergy Clin Immunol. 2015;135(5):1099-1106.
- Hill ID, Fasano A, Guandalini S, et al. NASPGHAN clinical report on the diagnosis and treatment of gluten-related disorders. J Pediatr Gastroenterol Nutr. 2016;63(1):156-165.
- Lebwohl B, Sanders DS, Green PHR. Coeliac disease. Lancet. 2018;391(10115):70-81.
